Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Oncolytics Biotech Inc (NQ: ONCY )

1.240 +0.010 (+0.81%)
Streaming Delayed Price Updated: 9:38 AM EDT, Aug 8, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,115
Open 1.230
Bid (Size) 1.240 (7)
Ask (Size) 1.270 (5)
Prev. Close 1.230
Today's Range 1.230 - 1.300
52wk Range 0.8021 - 2.381
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Global Pancreatic Cancer Therapeutics & Diagnostics Market Expected To Reach $5.6 Billion By 2027
Palm Beach, FL – June 28, 2022 – FinancialNewsMedia.com News Commentary – Pancreatic cancer therapeutics and diagnostics involve medical procedures used to diagnose pancreatic cancer and subsequent... 
Via FinancialNewsMedia
Oncolytics Reports Partnering With Biopharma Industry Leaders To Fast-Track Immunotherapy Treatment
This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. 
Via Benzinga

Performance

YTD
-12.68%
-12.68%
1 Month
+22.77%
+22.77%
3 Month
-3.88%
-3.88%
6 Month
-34.04%
-34.04%
1 Year
-43.64%
-43.64%

More News

Read More
A Preview Of Oncolytics Biotech's Earnings
Via Benzinga
HER2-Targeted Therapies Introduced Early in Breast Cancer Treatment Offering Hope for Patients
Via FinancialNewsMedia
Exposures COVID-19
Oncolytics Biotech® and SOLTI Present New Clinical Biomarker Data Demonstrating Pelareorep’s Potential to Improve the Prognosis of Breast Cancer Patients at the ESMO Breast Cancer Meeting
Via FinancialNewsMedia
Advancements of CAR-T Cell Therapies Importance Grows While Cancer Cases Increasing
Via FinancialNewsMedia
Oncolytics Expected To Announce Progress On New Glioblastoma Treatment This Spring
Via Benzinga
Recap: Oncolytics Biotech Q4 Earnings
Via Benzinga
Optimism Builds for Promising Developments & New Drug Therapies Targeting Treatments for Breast Cancer
Via FinancialNewsMedia
The Daily Biotech Pulse: NuCana Shelves Biliary Tract Cancer Study, Tricida Data Readout Pushed Back Due to Ukrainian Crisis, Synlogic Names New CFO
Via Benzinga
Earnings Scheduled For March 3, 2022
Via Benzinga
Preview: Oncolytics Biotech's Earnings
Via Benzinga
The Week Ahead In Biotech (Feb. 27-March 5): Earnings, Multiple Regulatory Decisions Take The Spotlight
Via Benzinga
This Biotech Company Reports Making Ground-Breaking Strides In Combating Solid Tumors
Via Benzinga
Oncolytics Reports Foothold In Chinese Pharmaceutical Market With Latest Breast Cancer Clinical Trials
Via Benzinga
Oncolytics Announced Updates On Clinical Trials Of New Treatment For Triple-Negative Metastatic Breast Cancer
Via Benzinga
Groundbreaking Clinical Trials Accelerating New Treatment Options for Pancreatic Cancer
Via FinancialNewsMedia
The Daily Biotech Pulse: LogicBio Genome Editing Therapy Study Placed On Clinical Hold, Gilead Q4 Disappoints On Slowing Veklury Sales
Via Benzinga
Promising Results Continue to Develop Optimism in Fight Against Cancers
Via FinancialNewsMedia
Oncolytics Biotech® Partner Adlai Nortye Advances to the Second Dose Escalation Cohort of the Chinese Bridging Trial Evaluating Pelareorep-Paclitaxel Combination Treatment in Breast Cancer
Via FinancialNewsMedia
R&D Spending Increases Exponentially for Higher Standard of Breast Cancer Drug Treatments
Via FinancialNewsMedia
Topics Death Intellectual Property
Exposures Death Intellectual Property
The Daily Biotech Pulse: Galapagos Appoints J&J Exec As CEO, Aridis Gets Funding For Antiviral Treatment, Moderna Starts Omicron-Specific Booster Study
Via Benzinga
Is Oncolytics Biotech's GOBLET Study Making Headway in the Fight Against Pancreatic and Colorectal Tumors?
Via Benzinga
Billions Flowing into Cancer Immunotherapy as Market Responds to Impressive Market Potential
Via FinancialNewsMedia
Promising Research in Fight Against Breast Cancer Being Amplified by an Active Biotech Sector
Via FinancialNewsMedia
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.